2018 is bringing new opportunities for Heffter's research mission. As the FDA Phase 3 work on psilocybin-assisted therapy for depression proceeds at the Usona Institute, Heffter is moving forward with its agenda to support research to test psilocybin's healing potential for other conditions, such as addictions, eating disorders, and Alzheimer's disease.
The work ahead is only possible because of the decades of work by scientists and supporters alike who are dedicated to psychedelic research and have been working together to bring a dream into reality.
